37 withdrawn. 37 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Withdrawn 37 |
| Phase 3 | 4 | Withdrawn 4 |
| Phase 1 | 2 | Withdrawn 2 |
Follow Behavioral Symptoms: new trials by email Literature Review of Behavioral Symptoms trials Research Report on Behavioral Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV Metformin, Placebo, Fluoxetine - Depression, Hiv | Phase 2 | Withdrawn | University of Minnesota | 2026-07-01 | 2026-07-10 | |
| Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies fMRI Neurofeedback, Accelerated theta burst stimulation, Psilocybin assisted therapy - Suicidal Ideation | Phase 2 | Withdrawn | University of New Mexico | 2026-05-01 | 2026-03-20 | |
| N2O for Acute Suicidality and Depression in the ED Nitrous oxide gas for inhalation, Placebo - Suicidal Ideation, Major Depressive Disorder | Phase 2 | Withdrawn | University of Chicago | 2026-02-27 | 2026-03-04 | |
| Dronabinol for Agitation in Dementia Crossover Trial Dronabinol - Dementia Moderate, Dementia Severe | Phase 2 | Withdrawn | Ralph H. Johnson VA Medical Center | 2023-11-01 | 2024-07-05 | |
| Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer Venlafaxine, Placebo - Head and Neck Cancer, Depression | Phase 2 | Withdrawn | Vanderbilt University Medical Center | 2023-08-01 | 2024-01-18 | |
| GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression Fisetin, GetHealthy-OA mind-body program, Placebo oral capsule - Knee Osteoarthritis, Obese | Phase 2 / Phase 3 | Withdrawn | Cale Andrew Jacobs, PhD | 2023-04-01 | 2023-05-01 | |
| Effect of SSRIs on Response to Psilocybin Therapy Psilocybin - Depression, Major Depressive Disorder | Phase 2 | Withdrawn | Cybin Therapeutics Inc. | 2023-01-01 | 2023-07-06 | |
| Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults PSIL428, Oyster mushroom - Anxiety and Depression | Phase 2 | Withdrawn | Wake Network, Inc. | 2022-09-15 | 2022-06-30 | |
| Intramuscular Ketamine for Suicidal Ideation Ketamine (Ketalar), Placebo - Suicidal Ideation | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2022-02-01 | 2022-04-05 | |
| A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day - Generalized Anxiety Disorder | Phase 2 | Withdrawn | AbbVie | 2021-08-18 | 2022-04-12 | |
| Antidepressant Effects of Nitrous Oxide Nitrous oxide gas for inhalation, Placebo - Major Depressive Disorder, Treatment Resistant Depression | Phase 2 | Withdrawn | University of Chicago | 2021-06-30 | 2026-05-14 | |
| Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation Nabilone, Placebo - Suicidal Ideation | Phase 2 | Withdrawn | The University of Texas Health Science Center, Houston | 2021-04-01 | 2021-09-22 | |
| Study of BXCL501 In Agitation Associated With Delirium in ICU Patients BXCL501, Placebo film - Agitation, Delirium | Phase 2 | Withdrawn | BioXcel Therapeutics Inc | 2021-02-23 | 2026-08-11 | |
| Dexmedetomidine Sublingual Film for the Management of Agitation in Delirium: Safety and Preliminary Efficacy Dexmedetomidine sublingual film - Delirium | Phase 2 | Withdrawn | Jeff C. Huffman, MD | 2020-06-01 | 2024-05-13 | |
| Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department Ketamine, Midazolam, Placebo - Acute Pain, Depression | Phase 2 / Phase 3 | Withdrawn | Maria Pacella | 2019-12-01 | 2020-02-11 | |
| ED Treatment of Suicidal Patients With Ketamine Infusion Ketamine - Suicide, Suicidal Ideation | Phase 2 | Withdrawn | University of California, Davis | 2019-04-01 | 2019-05-01 | |
| Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence Eluxadoline 100 mg, Placebo - Fecal Incontinence, Accidental Bowel Leakage | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-04-01 | 2019-07-25 | |
| Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine Lithium, Placebo, Ketamine - Treatment Resistant Depression | Phase 2 | Withdrawn | William V. Bobo, M.D. | 2017-11-30 | 2018-08-16 | |
| Mobile Phone App for Depression and Anxiety in Young Men Who Are Attracted to Men Mobile Phone Application - Depressive Symptoms, Anxiety Generalized | Phase 1 / Phase 2 | Withdrawn | Northwestern University | 2017-08-14 | 2017-08-17 | |
| Groups for Regaining Our Wellbeing (GROW) Mindfulness-Based Stress Reduction, Cognitive Processing Therapy - Posttraumatic Stress Disorder, Depression | Phase 2 / Phase 3 | Withdrawn | US Department of Veterans Affairs | 2014-04-01 | 2014-07-02 |
Showing 20 of 37. Sign in to see all of them.
Depression (28) · Depressive Disorder, Major (7) · Suicidal Ideation (6) · Anxiety Disorders (4) · Bipolar Disorder (4) · Depressive Disorder, Treatment-Resistant (3) · Psychomotor Agitation (3) · Stress Disorders, Post-Traumatic (3) · Delirium (2) · Generalized Anxiety Disorder (2) · Mood Disorders (2) · Pain (2) · Suicide (2) · Acquired Immunodeficiency Syndrome (1)
Behavior (36) · Mental Disorders (26) · Pathological Conditions, Signs and Symptoms (10) · Mood Disorders (9) · Signs and Symptoms (9) · Neurologic Manifestations (8) · Depressive Disorder (7) · Nervous System Diseases (6) · Self-Injurious Behavior (6) · Bipolar and Related Disorders (4) · Neurobehavioral Manifestations (4) · Neurocognitive Disorders (4) · Suicide (4) · Aberrant Motor Behavior in Dementia (3)
Ketamine (4) · Dexmedetomidine (2) · Endothelium-Dependent Relaxing Factors (2) · Inhalation (2) · Nitrous Oxide (2) · Psilocybin (2) · Transcranial Magnetic Stimulation (2) · 2-cyclohexylidenhydrazo-4-phenyl-thiazole (1) · Ceftriaxone (1) · Citalopram (1) · Dronabinol (1) · Fluoxetine (1) · Lithium (1) · Lithium Carbonate (1) · Metformin (1)
National Institute of Mental Health (NIMH) (2) · US Department of Veterans Affairs (2) · University of Chicago (2) · AbbVie (1) · BioXcel Therapeutics Inc (1) · Boston Children's Hospital (1) · Cale Andrew Jacobs, PhD (1) · Cybin Therapeutics Inc. (1) · Icahn School of Medicine at Mount Sinai (1) · James J. Peters Veterans Affairs Medical Center (1) · Jeff C. Huffman, MD (1) · Johns Hopkins University (1) · Maria Pacella (1) · Multidisciplinary Association for Psychedelic Studies (1) · New York State Psychiatric Institute (1)
United States (24) · Australia (1) · Canada (1) · Germany (1) · Jamaica (1) · Norway (1) · Sweden (1)
Peter Nagele, MD, MSc (2) · Aimee Moulin, MD (1) · Antonio Mantovani, MD, PhD (1) · BioXcel MM, MD (1) · Cale Jacobs, PhD (1) · Charles DeBattista, DMH, MD (1) · Christopher P Cardozo, M.D. (1) · Daniel Javitt, MD, PhD (1) · David J. Kearney, MD (1) · F. Andrew Kozel, MD, MSCR (1) · Irving Reti, M.B.B.S (1) · Jacobo E Mintzer, MD (1) · Jeff C Huffman, MD (1) · Jessica E Broadway, MD (1)
K08MH094441 (1)